FrancophonIA/ELRC3.0 huggingface dataset:
English: • women who do not produce eggs and do not respond to treatment with clomiphene citrate
Maltese: • nisa li ma jipproduċux bajd u li ma jirrispondux għall-kura bi clomiphene citrate (mediċina oħra li tistimula lill-ovarji sabiex jipproduċu l-bajd);
English: How does Ovaleap work?
Maltese: Kif jintuża Ovaleap?
English: ATCvet code: QI02AD02.
Maltese: QI02AD02
English: 50 doses (100 ml)
Maltese: 50 doża (100 ml)
English: Lyophilisate:
Maltese: Lijofilizat:
English: CONTRAINDICATION
Maltese: KONTRAINDIKAZZJONI
English: * Bovine viral diarrhoea virus ** Tissue culture infectious dose 50%
Maltese: * Virus tad-dijarea virali tal-ifrat ** Doża infettiva f'kultura tat-tessut 50%
English: Sodium chloride Potassium chloride Potassium dihydrogen phosphate Disodium hydrogen phosphate Water for injections
Maltese: Sodium chloride Potassium chloride Potassium dihydrogen phosphate Disodium hydrogen phosphate Ilma għal injezzjonijiet
English: Each dose (2 ml) contains: Lyophilisate:
Maltese: Kull doża (2 ml) fiha: Lijofilizat:
English: Potassium hydroxide L-Glutamine acid Potassium dihydrogen phosphate Dipotassium phosphate Sodium chloride Water for injections
Maltese: Potassium hydroxide L-Glutamine acid Potassium dihydrogen phosphate Dipotassium phosphate Sodium chloride Ilma għal injezzjonijiet
English: 5 doses (10 ml) 10 doses (20 ml) 25 doses (50 ml)
Maltese: 5 dożi (10 ml) 10 doż (20 ml) 25 doża (50 ml)
English: 5 doses (10 ml) 10 doses (20 ml) 25 doses (50 ml) 50 doses (100 ml) 4 x 5 doses (10 ml) 4 x 10 doses (20 ml) 4 x 25 doses (50 ml) 4 x 50 doses (100 ml) 6 x 5 doses (10 ml) 6 x 10 doses (20 ml) 6 x 25 doses (50 ml) 6 x 50 doses (100 ml) 10 x 5 doses (10 ml) 10 x 10 doses (20 ml) 10 x 25 doses (50 ml) 10 x 50 doses (100 ml)
Maltese: 5 dożi (10 ml) 10 dożi (20 ml) 25 doża(50 ml) 50 doża (100 ml) 4 x 5 dożi (10 ml) 4 x 10 dożi (20 ml) 4 x 25 doża (50 ml) 4 x 50 doża (100 ml) 6 x 5 dożi (10 ml) 6 x 10 dożi (20 ml) 6 x 25 doża (50 ml) 6 x 50 doża (100 ml) 10 x 5 dożi (10 ml) 10 x 10 dożi (20 ml) 10 x 25 doża (50 ml) 10 x 50 doża (100 ml)
English: Veterinary medicinal product subject to prescription.
Maltese: kwalunkwe prodott mediċinali veterinarju.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal trattat) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal trattat) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal trattat) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal trattat, inklużi rapporti iżolati).
English: For active immunisation of cattle from 3 months of age to reduce hyperthermia and to minimise the reduction of leukocyte count caused by bovine viral diarrhoea virus (BVDV-1 and BVDV-2), and to reduce virus shedding and viraemia caused by BVDV-2.
Maltese: Għal tilqima attiva minn 3 xhur ta' età biex titnaqqas l-ipertermija u biex jiġi mminimizzat it-tnaqqis tal-għadd ta' lewkoċiti kkawżat mill-virus tad-dijarea virali tal-ifrat (BVDV-1 u BVDV-2), u biex jitnaqqas it-tixrid virali (virus shedding) u viremija kkawżati minn BVDV-2.
English: Hypersensitivity reactions, including anaphylactic-type reactions, have been reported very rarely (post-marketing safety experience).
Maltese: Reazzjonijiet ta' sensittività eċċessiva, inklużi reazzjonijiet tat-tip anafilattiċi, ġew irrapurtati rari ħafna (esperjenza ta' sigurtà wara t-tqegħid fis-suq).
English: Date of first authorisation: 22.12.2014 Date of last renewal:
Maltese: Data tal-ewwel awtorizzazzjoni: 22.12.2014
English: For active immunisation of cattle against BVDV-1 and BVDV-2, to prevent the birth of persistently infected calves caused by transplacental infection.
Maltese: Għal tilqima attiva ta' baqar kontra l-BVDV-1 u BVDV-2, għal prevenzjoni ta' twelid ta' għoġġiela infettati b'mod persistenti minn infezzjoni transplaċentali.
English: Solvent for Bovela
Maltese: ŻMIEN TA' TIŻMIM
English: Each dose (2 ml) contains: BVDV-1: 104.0-106.0 TCID50, BVDV-2: 104.0-106.0 TCID50.
Maltese: TCID50, BVDV-2: 104.0-106.0 TCID50
English: After reconstitution, administer one dose (2 ml) of the vaccine by intramuscular (IM) injection.
Maltese: (2 ml) tat-tilqima permezz ta' injezzjoni ġol-muskoli (IM).
English: EU/2/14/176/013 50 doses EU/2/14/176/014 4 x 50 doses EU/2/14/176/015 6 x 50 doses EU/2/14/176/016 10 x 50 doses
Maltese: EU/2/14/176/013 50 doża EU/2/14/176/014 4 x 50 doża EU/2/14/176/015 6 x 50 doża EU/2/14/176/016 10 x 50 doża
English: 8 hours.
Maltese: 8 sigħat
English: Bovine viral diarrhoea virus type 1: 104.0-106.0 TCID50, Bovine viral diarrhoea virus type 2: 104.0-106.0 TCID50.
Maltese: Virus tad-Dijarea Virali tal-Ifrat Tip 1: 104.0-106.0
English: Pharmacotherapeutic group: immunologicals for bovidae, live viral vaccines.
Maltese: Grupp farmako-terapewtiku: immunoloġiċi għal bovidae, tilqim virali ħaj
English: Name and address of the manufacturer of the biological active substance Boehringer Ingelheim Animal Health USA Inc. 2621 North Belt Highway, St. Joseph, Missouri, 64506-2002 USA
Maltese: Inc. 2621 North Belt Highway, St.
English: Gelatine
Maltese: KWANTITÀ
English: High density polyethylene (HDPE) bottles sof solvent, closed with a siliconised chlorobutyl rubber stopper with lacquered aluminium seal.
Maltese: Fliexken tal-polyethylene b'densità għolja (High Density Polyethylene, HDPE) li jkun fihom solvent, magħluqin b'tapp tal-lastku tal-chlorobutyl silikonizzat b'siġill tal-aluminju bil-verniċ.
English: EU/2/14/176/001 5 doses and 10 ml EU/2/14/176/002 5 doses and 10 ml (4 x) EU/2/14/176/003 5 doses and 10 ml (6 x) EU/2/14/176/004 5 doses and 10 ml (10 x)
Maltese: EU/2/14/176/002 5 dożi u 10 ml (4 x) EU/2/14/176/003 5 dożi u 10 ml (6 x)
English: Interaction with other medical products and other forms of interaction:
Maltese: Interazzjoni ma' prodotti mediċinal oħrajn u forom oħrajn ta' interazzjoni:
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Lyophilisate vials: 50 doses
Maltese: Kunjetti bil-lijofilizzat: 50 doża
English: Longlasting viremia has been observed after vaccination, in particular in pregnant seronegative heifers (10 days in a study).
Maltese: Viremija li ddum għal tul ta' żmien ġiet osservata wara t-tilqima, b'mod partikulari f'erieħ seronegattivi tqal (10 ijiem fi studju).
English: Modified live BVDV*-1, non-cytopathic parent strain KE-9: 104.0-106.0 TCID50**, Modified live BVDV*-2, non-cytopathic parent strain NY-93: 104.0-106.0 TCID50**.
Maltese: Razza ġenitur NY-93 mhux ċitopatika modifikata ħajja BVDV*-2: 104.0-106.0
English: Read the package leaflet before use.
Maltese: Mhux id-daqsijiet kollha tal-pakkett jistgħu jitqiegħdu fis-suq.
English: The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Maltese: L-addittivi (inkluż l-aġġuvanti) elenkati f'sezzjoni 6.1 tal-Karatteristiċi tal-Prodott fil-Qosor huma jew sustanzi ammissibbli li għalihom m'hemmx bżonn ta' limiti massimi ta' residwi kif indikat fit-tabella numru 1 tal-anness tar-Regolament tal-Kummissjoni (UE) Nru 37/2010 jew huma kunsidrati li ma jaqgħux fi ħdan l-iskop tar-Regolament (KE) Nru 470/2009 meta użati bħal f'dan il-prodott mediċinali veterinarju.
English: Additional laboratory tests to differentiate vaccine strain virus from field strain are available upon request from the marketing authorisation holder.
Maltese: Testijiet addizzjonali fil-laboratorji biex issir distinzjoni bejn il-virus tar-razza tat-tilqima u r-razza tal-kamp huma disponibbli fuq talba tad-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box: 5 doses, 10 doses, 25 doses, 50 doses lyophilisate and 10 ml, 20 ml, 50 ml, 100 ml solvent
Maltese: Kaxxa tal-kartun: 5 dożi, 10 dożi, 25 doża, 50 doża ta' lijofilizat u 10 ml, 20 ml, 50 ml, 100 ml ta' solvent
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Solvent bottles: 10 ml, 20 ml, 50 ml, 100 ml
Maltese: Fliexken bis-solvent: 10 ml, 20 ml, 50 ml, 100 ml
English: A definitive diagnosis of persistent infection can only be established upon re-testing in blood after an interval of at least 3 weeks.
Maltese: Dijanjosi definittiva ta' infezzjoni persistenti tista' tiġi stabbilita biss meta jsir ittestjar mill-ġdid fid-demm wara intervall ta' mill-inqas 3 ġimgħat.
English: Primary vaccination:
Maltese: Tilqima primarja:
English: Bovela lyophilisate and solvent for suspension for injection for cattle
Maltese: VETERINARJU Bovela lijofilizat u solvent għal suspensjoni għall-injezzjoni għal ifrat
English: Lyophilisate and solvent for suspension for injection
Maltese: GĦAMLA FARMAĊEWTIKA Lijofilizat u solvent għal suspensjoni għall-injezzjoni
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate vials: 5 doses, 10 doses and 25 doses
Maltese: Kunjetti bil-lijofilizzat: 5 dożi, 10 dożi u 25 doża
English: Zero days.
Maltese: Xejn jiem.
English: Bovela lyophilisate for suspension for injection for cattle
Maltese: VETERINARJU Bovela lijofilizat għal suspensjoni għall-injezzjoni għal ifrat
English: EU/2/14/176/005 10 doses and 20 ml EU/2/14/176/006 10 doses and 20 ml (4 x) EU/2/14/176/007 10 doses and 20 ml (6 x) EU/2/14/176/008 10 doses and 20 ml (10 x) EU/2/14/176/009 25 doses and 50 ml EU/2/14/176/010 25 doses and 50 ml (4 x) EU/2/14/176/011 25 doses and 50 ml (6 x) EU/2/14/176/012 25 doses and 50 ml (10 x) EU/2/14/176/013 50 doses and 100 ml EU/2/14/176/014 50 doses and 100 ml (4 x) EU/2/14/176/015 50 doses and 100 ml (6 x) EU/2/14/176/016 50 doses and 100 ml (10 x)
Maltese: EU/2/14/176/013 50 doża u 100 ml EU/2/14/176/014 50 doża u 100 ml (4 x) EU/2/14/176/015 50 doża u 100 ml (6 x) EU/2/14/176/016 50 doża u 100 ml (10 x)
English: It is recommended to vaccinate before pregnancy to ensure protection against persistent infection of the foetus.
Maltese: Hu rakkomandat li tagħti t-tilqima qabel it-tqala biex tiżgura protezzjoni kontra infezzjoni persistenti tal-fetu.
English: Animals which are vaccinated later than 3 weeks before gestation or during the early gestation may not be protected against foetal infection.
Maltese: Annimali li jiġu mlaqqma aktar tard minn 3 ġimgħat qabel il-ġestazzjoni jew kmieni fil-ġestazzjoni, jistgħu ma jkunux protetti kontra infezzjoni fetali.
English: According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:
Maltese: Skont l-Artikolu 71 tad-Direttiva 2001/82/KEE tal-Parlament Ewropew u tal-Kunsill, kif emendata, Stat Membru jista', skont il-liġijiet nazzjonal tiegħu, jipprojbixxi l-manifattura, l-importazzjoni,
English: Intramuscular use.
Maltese: Sena wara t-tilqima.
English: The active substance being a principle of biological origin intended to produce active immunity is not in the scope of Regulation (EC) 470/2009.
Maltese: Is-sustanza attiva li hija prinċipju ta' oriġini bijoloġiku maħsuba sabiex tipproduċi immunità attiva ma taqax fi ħdan l-iskop tar-Regolament (KE) Nru 470/2009.
English: Shelf life of the solvent:
Maltese: Żmien kemm idum tajjeb is-solvent:
English: 4 lyophilisate vials of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 4 solvent bottles of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box.
Maltese: 4 kunjetti lijofilizat ta' 10 mL (5 dożi), 20 mL (10 dożi), 50 mL (25 doża) jew 100 mL (50 doża) u 4 iflixken solvent ta' 10 mL, 20 mL, 50 mL jew 100 mL ippakkjati f'kaxxa tal-kartun.
English: 6 lyophilisate vials of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 6 solvent bottles of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box.
Maltese: 6 kunjetti lijofilizat ta' 10 mL (5 dożi), 20 mL (10 dożi), 50 mL (25 doża) jew 100 mL (50 doża) u 6 iflixken solvent ta' 10 mL, 20 mL, 50 mL jew 100 mL ippakkjati f'kaxxa tal-kartun.
English: While persistent infection of the foetus caused by the vaccine was not observed, transmission of vaccine virus to the foetus may occur..
Maltese: Filwaqt li infezzjoni persistenti tal-fetu kkawżata mil-virus ma ġietx osservata, it-trażmissjoni tal-virus tat-tilqima lill-fetu tista' tokkorri.
English: 10 lyophilisate vials of 10 ml (5 doses), 20 ml (10 doses), 50 ml (25 doses) or 100 ml (50 doses) and 10 solvent bottles of 10 ml, 20 ml, 50 ml or 100 ml packed in one cardboard box.
Maltese: 10 kunjetti lijofilizzat ta' 10 mL (5 dożi), 20 mL (10 dożi), 50 mL (25 doża) jew 100 mL (50 doża) u 10 iflixken solvent ta' 10 mL, 20 mL, 50 mL jew 100 mL ippakkjati f'kaxxa talkartun.
English: Do not mix with any other veterinary medicinal product, except solvent supplied for use with the veterinary medicinal product.
Maltese: Tħallatx ma' ebda prodott mediċinali veterinarju ieħor ħlief mas-solvent ipprovdut għal użu ma' dan il-prodott mediċinali veterinarju.
English: Therefore, use during pregnancy should only be on a case-by-case basis decided by the responsible veterinarian, taking into consideration e.g. the BVD immunological status of the animal, the time-span between vaccination and mating/insemination, the stage of pregnancy and the risk of infection.
Maltese: L-istat immunoloġiku tal-BVD tal-annimal, l-intervall bejn it-tilqima u t-tgħammir/inseminazzjoni, l-istadju tat-tqala u r-riskju ta' infezzjoni.
English: Mild swellings or nodules up to 3 cm diameter were observed at the injection site after administration of a 10-fold overdose and disappeared within 4 days post vaccination.
Maltese: Nefħiet ħfief jew għoqod b'dijametru sa 3 ċm ġew osservati fis-sit tal-injezzjoni wara l-għoti ta' doża eċċessiva ta' 10 darbiet aktar, u sparixxew fi żmien 4 ijiem wara t-tilqima.
English: The vaccine is designed to stimulate the development of an active immune response against BVDV-1 and BVDV-2 in cattle.
Maltese: It-tilqima hi maħsuba biex tistimula l-iżvilupp ta' rispons attiv ta' immunità kontra BVDV-1 u BVDV2 fl-ifrat.
English: • dementia (loss of intellectual function).
Maltese: • demenzja (telf ta' funzjoni intellettwali).
English: Further information on Striascan can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/striascan.
Maltese: ema.europa.eu/medicines/human/EPAR/striascan.
English: Striascan is a diagnostic medicine.
Maltese: Striascan huwa mediċina dijanjostika.
English: Other information about Striascan
Maltese: Informazzjoni oħra dwar Striascan
English: A scan is taken 3 to 6 hours after the injection.
Maltese: Jittieħed scan 3 sigħat sa 6 sigħat wara l-injezzjoni.
English: • movement disorders such as those in Parkinson's disease and other related diseases, where a loss of nerve cells leads to tremor (shaking), gait disturbance (problems with the way the patient walks) and stiffness of the muscles.
Maltese: • disturbi fil-moviment bħal dawk tal-marda ta' Parkinson u mard relatat ieħor, fejn telf ta' ċelloli tan-nervituri jwassal għal rogħda (xengil), disturb fil-mixja (problemi fil-mod ta' kif il-pazjent jimxi) u ebusija fil-muskoli.
English: It contains a substance called ioflupane, which is labelled with 123I (iodine-123), a radioactive form of iodine.
Maltese: Hi fiha sustanza msejħa ioflupan, li hija ttikkettata b'123l (jodju-123), forma radjuattiva ta' jodju.
English: This build-up can be seen using an imaging technique called single-photon-emission computed tomography (SPECT), which detects the radioactive iodine-123.
Maltese: Din l-akkumulazzjoni tista' tidher bl-użu ta' teknika talimmaġni msejħa tomografija kompjuterizzata b'emissjoni waħda ta' foton (single-photon-emission computed tomography - SPECT), li tidentifika l-jodju radjuattiv-123.
English: Striascan (ioflupane (
Maltese: Striascan (ioflupan (123I))
English: Striascan is given by slow injection lasting at least 15 to 20 seconds into an arm vein.
Maltese: Striascan jingħata b'injezzjoni bil-mod li ddum minn tal-inqas 15 sa 20 sekonda f'vina tad-driegħ.
English: For more information on generic medicines, see the question-and-answer document here.
Maltese: Għal aktar informazzjoni dwar il-mediċini ġeneriċi, ara d-dokument mistoqsijietutweġibiet hawnhekk.
English: Striascan is used to help distinguish between a type of dementia known as ‘dementia with Lewy bodies' and Alzheimer's disease.
Maltese: demenzja magħrufa bħala ‘demenzja bil-Lewy bodies' u l-marda tal-Alzheimer.
English: Side effects reported with Striascan are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati bi Striascan huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: How is Striascan used?
Maltese: Striascan?
English: This enables diseases related to Parkinson's disease to be distinguished from essential tremor, and for Lewy body dementia to be distinguished from Alzheimer's disease.
Maltese: Dan jippermetti li ssir distinzjoni bejn il-mard ta' Parkinson u r-rogħda essenzjali, u distinzjoni bejn iddemenzja bil-Lewy bodies u l-marda tal-Alzheimer.
English: How has Striascan been studied?
Maltese: Kif ġie studjat Striascan?
English: Because Striascan is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Striascan huwa mediċina ġenerika, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk talmediċina ta' referenza.
English: Striascan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called DaTSCAN.
Maltese: Dan ifisser li Striascan fih listess sustanza attiva u jaħdem bl-istess mod bħal ‘mediċina ta' referenza' diġà awtorizzata fl-UE msejħa DaTSCAN.
English: In patients with Parkinson's disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of the dopamine-containing nerve cells in the striatum.
Maltese: F'pazjenti bil-marda ta' Parkinson u mard relatat, u f'pazjenti bid-demenzja bil-Lewy bodies, tipikament ikun hemm telf taċ-ċelloli tan-nervituri li fihom id-dopamina fl-istratum.
English: Resuscitation equipment should be available before Striascan is given, in case the patient has an allergic reaction.
Maltese: Apparat għar-risuxxitazzjoni għandu jkun disponibbli qabel ma jingħata Striascan, f'każ li l-pazjent ikollu reazzjoni allerġika.
English: What are the benefits and risks of Striascan?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Striascan?
English: As for all medicines, data on the use of Striascan are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Striascan hija ssorveljata kontinwament.
English: There was no need for ‘bioequivalence' studies to investigate whether Striascan is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Maltese: Ma kienx hemm bżonn ta' studji ta' ‘bijoekwivalenza' biex jiġi investigat jekk Striascan jiġix assorbit b'mod simili għall-mediċina ta' referenza biex jipproduċi l-istess livell tas-sustanza attiva fid-demm.
English: Between 1 to 4 hours before receiving Striascan, patients must also take another medicine, such as iodine tablets, to prevent the radioactive iodine in Striascan from getting into the thyroid gland.
Maltese: Bejn siegħa u 4 sigħat qabel ma jirċievu Striascan, il-pazjenti għandhom jieħdu wkoll mediċina oħra, bħall-pilloli tal-jodju, biex jipprevjenu l-jodju radjuattiv fi Striascan milli jidħol fil-glandola tat-tirojde.
English: Striascan is only handled and given by people who have experience in the safe handling of radioactive materials.
Maltese: Striascan jista' jiġi mmaniġġjat u mogħti biss minn persuni li għandhom esperjenza fl-immaniġġjar sigur ta' materjali radjuattivi.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, DaTSCAN, and do not need to be repeated for Striascan.
Maltese: Studji dwar il-benefiċċji u r-riskji tas-sustanza attiva fl-użu awtorizzat diġà twettqu bil-mediċina ta' referenza, DaTSCAN, u m'għandhomx għalfejn jiġu ripetuti għal Striascan.
English: Ioflupane attaches specifically to structures on nerve cell endings that are responsible for the transport of dopamine.
Maltese: L-ioflupan teħel b'mod speċifiku mal-istrutturi fuq it-truf taċ-ċelloli tan-nervituri li huma responsabbli mit-trasport taddopamina.
English: It is used to detect the loss of nerve cells in an area of the brain called the striatum, specifically the cells that release dopamine, a chemical messenger.
Maltese: Informazzjoni dwar il-mediċina ta' referenza tinstab ukoll fis-sit elettroniku tal-Aġenzija.
English: Striascan can only be obtained with a prescription and should only be used in patients who have been referred by a doctor with experience in the management of movement disorders or dementia.
Maltese: Striascan jista' jinkiseb biss b'riċetta ta' tabib u għandu jintuża biss minn pazjenti li ġew irreferuti minn tabib b'esperjenza fil-ġestjoni ta' disturbi fil-moviment jew ta' demenzja.
English: EMA/25046/2016 EMEA/H/C/000669
Maltese: EMA/25046/2016 EMA/H/C/000669
English: The full EPAR for RotaTeq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: RotaTeq rotavirus vaccine, live
Maltese: RotaTeq vaċċin rotavirus, ħaj
English: It contains five live rotavirus strains, each carrying a different antigen (G1, G2, G3, G4 and P1[8]).
Maltese: Jiġi f'soluzzjoni f'tubu b'doża singola. I kun fih ħames razez ħajjin ta' rotavirus, u kull wieħed iġorr antiġen differenti (G1, G2, G3, G4 and P1[8]).
English: Other information about RotaTeq:
Maltese: Informazzjoni oħra dwar RotaTeq:
English: Overall, the studies of RotaTeq involved over 72,000 babies, including about 2,000 premature babies.
Maltese: Kollox ma' kollox, l-istudji ta' RotaTeq involvew ‘il fuq minn 72,000 tarbija, inklużi 2,000 tarbija prematura.
English: This document is a summary of the European public assessment report (EPAR) for RotaTeq.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal RotaTeq.
English: There are various types of rotaviruses that cause gastroenteritis.
Maltese: Hemm diversi tipi ta' rotaviruses li jikkawżaw il-gastroenterite.
English: Among the almost 6,000 babies in whom the main measure of effectiveness was studied, 82 of the babies vaccinated with RotaTeq developed rotavirus gastroenteritis (one with severe gastroenteritis) compared with 315 of the babies who received placebo (51 severe cases).
Maltese: Fost il-kważi 6,000 tarbija li fihom ġie studjat il-kejl ewlieni taleffikaċja, 82 tarbija li ngħataw it-tilqima b'RotaTeq żviluppatilhom ir-rotavirus gastroenterite (tarbija minnhom b'gastroenterite gravi) meta mqabbla ma' 315-il tarbija li ngħataw il-plaċebo (51 każ gravi).
English: If necessary it may be given up to the age of 32 weeks.
Maltese: Jekk ikun meħtieġ, din tista' tingħata sal-età ta' 32 ġimgħa.
English: RotaTeq is used in babies from 6 to 32 weeks of age to protect against gastroenteritis (diarrhoea and vomiting) caused by rotavirus infections.
Maltese: RotaTeq jintuża fi trabi li jkollhom minn 6 ġimgħat sa 32 ġimgħa biex jipproteġihom mill-gastroenterite (dijarrea u remettar) ikkawwżati minn infezzjonijiet tar-rotavirus.